5-氨基酮戊酸光动力治疗对鲍温病皮损中p53 Caveolin-1表达的影响

doi:10.3969/j.issn.1006-6233.2024.05.016

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (3314 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the influence and significance of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) on the expression of p53 and Caveolin-1 in Bowen's disease (BD) lesions. Methods: Forty cases of Bowen's disease and adjacent normal skin tissues were treated with ALA-PDT. Immunohistochemical staining (SP method) was used to detect the positive expression rates of p53 and Caveolin-1 in BD and surrounding normal skin tissues before and after photodynamic therapy. Results: Before treatment, the positive rates of p53 protein expression in normal skin tissue and BD were 10% and 40%, respectively (χ²=11.202, P＜0.001), with a statistically significant difference. After treatment, the positive rates of p53 in normal skin tissue and BD were 10% and 5% (χ²=0.712, P=0.399), respectively, with no statistically significant difference between them. The difference in the positive expression rate of p53 in BD before and after treatment was statistically significant (χ²=14.811, P＜0.001). Before treatment, the positive expression rates of Caveolin-1 in normal skin tissue and BD were 15% and 55%, respectively (χ²=14.449, P＜0.001), with a statistically significant difference. After treatment, the positive rates of Caveolin-1 in normal skin tissue and BD were 5% and 12.5% (χ²=0.816, P=0.366), respectively, with no statistically significant difference between them. The difference in the positive expression rate of Caveolin-1 in BD before and after treatment was statistically significant (χ²=19.013, P＜0.001). There was a positive correlation between p53 and Caveolin-1 expression in BD (r=0.533, P=0.015). Conclusion: The high expression of p53 and Caveolin-1 may be closely related to the occurrence of BD, and ALA-PDT can inhibit the expression of p53 and Caveolin-1, thereby inhibiting the progression of the disease. With a larger sample size, p53 and Caveolin-1 may become diagnostic tools for skin-related diseases and provide new targets for their treatment.

Key words： 5-aminoketovaleric acid photodynamic therapy Bowen's disease p53 Caveolin-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.05.016 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I5/794

[1] 熊林,陆延娜,万静,等.5-氨基酮戊酸光动力疗法治疗鲍温病10例疗效观察 [J].中国皮肤性病学杂志,2012,26(2):124-125.
[2] O'connell K A,Okhovat J P,Zeitouni N C.Photodynamic therapy for bowen's disease (squamous cell carcinoma in situ) current review and update [J].Photodiagnosis and Photodynamic Therapy,2018,24(12):109-114.
[3] 庄丽珍.氨基酮戊酸光动力疗法治疗皮肤癌前病变及浅表皮肤癌的临床效果及复发率探讨 [J].中华肿瘤防治杂志,2020,27(1):163-165.
[4] 魏云,吴丽娟,,丁高中,等. Caveolin-1、Met蛋白在日光性角化病、鲍温病和皮肤鳞状细胞癌中的表达 [J].中国麻风皮肤病杂志,2019,35(5):276-279.
[5] Morton C,Horn M,Leman J,et al.Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ:results of a multicenter randomized trial [J].Archives of Dermatology,2006,142(6):729-735.
[6] M O,Koskenimies S,Pitknen S.A retrospective study of treatment of squamous cell carcinoma in situ [J].Acta dermato-venereologica,2016,96(1):64-67.
[7] 章申峰,龚兴国.光动力疗法对肿瘤的作用机制及其影响因素 [J].细胞生物学杂志,2005(4):395-399.
[8] Bagazgoitia L,Cuevas J,Juarranza.Expression of p53 and p16 in actinic keratosis,bowenoid actinic keratosis and Bowen's disease [J].Journal of the European Academy of Dermatology & Venereology,2010,24(2):228-230.
[9] Batinac T,Zamolo G,Jonji N,et al.p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases [J].Tumori,2004,90(1):120.
[10] Talghini S,Halimi M,Baybordi H.Expression of P27,Ki67 and P53 in squamous cell carcinoma,actinic keratosis and bowen disease [J].Pakistan Journal of Biological Sciences Pjbs,2009,12(12):929.
[11] 邹爱玲,石年,石娴,等.p53及p16在皮肤鳞状细胞癌和鲍温病中的表达及意义 [J].中国中西医结合皮肤性病学杂志,2019,18(4):293-298.
[12] Pin F,Fu-chun C,Qi P,et al.The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma [J].Onco Targets Ther,2017(10):819-835.
[13] Cao Wenbo,Zhao,et al.Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1 [J].Tumour biology,2016,37(7):9189-9196.
[14] Trimmer C,Sotgia F,Lisanti M P,et al.Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation [J].American Journal of Translational Research,2013,5(1):80-91.